| 51 |
26100670 | Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy. | 2015 Sep 1 |
2 |
| 52 |
26169036 | Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. | 2015 Sep |
1 |
| 53 |
26257239 | Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. | 2015 Dec |
1 |
| 54 |
26301220 | Repression of CD24 surface protein expression by oncogenic Ras is relieved by inhibition of Raf but not MEK or PI3K. | 2015 |
1 |
| 55 |
26324075 | Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. | 2015 Nov |
1 |
| 56 |
26488287 | Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. | 2015 Oct |
1 |
| 57 |
23543326 | Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. | 2014 Mar |
1 |
| 58 |
23879247 | Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. | 2014 Mar |
1 |
| 59 |
24096267 | Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. | 2014 Jan |
2 |
| 60 |
24170769 | Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. | 2014 Jan |
1 |
| 61 |
24375110 | VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment. | 2014 May |
1 |
| 62 |
24378831 | Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. | 2014 Mar |
1 |
| 63 |
24606495 | Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors. | 2014 Jun |
3 |
| 64 |
24692700 | Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. | 2014 Apr |
1 |
| 65 |
24714776 | Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. | 2014 Jun 15 |
1 |
| 66 |
24936068 | B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells. | 2014 Aug 15 |
1 |
| 67 |
24965413 | Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells. | 2014 Apr-Jun |
1 |
| 68 |
25376291 | Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma. | 2014 |
1 |
| 69 |
25607711 | A case of new onset keratosis pilaris after discontinuation of erlotinib. | 2014 Nov |
1 |
| 70 |
26158148 | Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. | 2014 Jun |
1 |
| 71 |
27508178 | Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. | 2014 |
2 |
| 72 |
22751450 | Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. | 2013 Feb |
1 |
| 73 |
22941213 | Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. | 2013 Jan |
5 |
| 74 |
22973961 | Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells. | 2013 |
1 |
| 75 |
23224737 | A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation. | 2013 Feb 1 |
1 |
| 76 |
23255896 | Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. | 2013 Jan |
1 |
| 77 |
23340175 | Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells. | 2013 May 1 |
2 |
| 78 |
23412107 | In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours. | 2013 Apr 2 |
3 |
| 79 |
23467984 | Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells. | 2013 May |
1 |
| 80 |
23497499 | Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. | 2013 Mar 6 |
1 |
| 81 |
23562168 | Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. | 2013 Aug |
1 |
| 82 |
23591401 | A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. | 2013 Jul |
1 |
| 83 |
23908594 | Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. | 2013 Aug |
2 |
| 84 |
23953412 | Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation. | 2013 Nov |
1 |
| 85 |
24331695 | [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism]. | 2013 Nov |
3 |
| 86 |
24391798 | BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. | 2013 |
3 |
| 87 |
24460304 | Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. | 2013 |
1 |
| 88 |
21751200 | Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. | 2012 Feb 1 |
1 |
| 89 |
21858812 | Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. | 2012 Aug 1 |
1 |
| 90 |
21979753 | Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). | 2012 Feb 10 |
3 |
| 91 |
22056813 | Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. | 2012 Jan 28 |
1 |
| 92 |
22096025 | Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. | 2012 Jan 1 |
1 |
| 93 |
22190165 | Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. | 2012 Mar |
1 |
| 94 |
22214462 | Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. | 2012 |
4 |
| 95 |
22261591 | PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. | 2012 Aug |
4 |
| 96 |
22357220 | Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. | 2012 Jun |
2 |
| 97 |
22451120 | Sorafenib for treatment of hepatocellular carcinoma: a systematic review. | 2012 May |
1 |
| 98 |
22514082 | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. | 2012 Dec 15 |
1 |
| 99 |
22519770 | Sorafenib in liver cancer. | 2012 May |
2 |
| 100 |
22520038 | Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. | 2012 Apr 21 |
2 |